Dublin, Ireland, November 3, 2014
Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that it has been named ‘Start-up Company of the Year’ at the inaugural Pharma Industry Awards 2014. This ‘Start-up Company of the Year’ award was open to any company established within the last 3 years in the biotech, biopharma or pharmaceutical sector in Ireland.
Darren Cunningham, Co-Founder and Chief Executive Officer of Inflection Biosciences, commented ‘We are very pleased to accept the award on behalf of all those who have contributed to Inflection Biosciences since its establishment in 2012. We have made great progress towards our aim of developing groundbreaking new treatments for those suffering with cancer and this recognition as leading start-up in the sector will provide further momentum towards achieving our goals.’
About the Pharma Industry Awards The Pharma Industry Awards recognise and celebrate the most original and innovative individuals and companies that demonstrate excellence in the Irish Pharma sector. The winners were announced at The Pharma Industry Awards 2014 on Wednesday, October 29th at the Ballsbridge Hotel, Dublin 4. For more information please visit www.pharmaawards.ie
About Inflection Biosciences Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises a unique dual mechanism pan-PIM/PI3 kinase inhibitor program and a pan-PIM kinase inhibitor program, both in preclinical development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. For more information please visit the Company’s website at www.inflectionbio.com